Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

Medically reviewed by Nicholas R. Metrus, MDMedically reviewed by Nicholas R. Metrus, MD The most common symptom of ...

Unless your partner has mentioned it, odds are you don't know for certain whether you sleep with your mouth open or drool.

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...

Kenny Chesney, left, and Carly Pearce perform "You and Tequila" together at St. Joseph's Health Amphitheater at Lakeview in ...

Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...

Myasthenia gravis is an autoimmune condition that weakens the muscles in your body. Acetylcholine is a neurotransmitter that helps your muscles move. Most people with generalized myasthenia gravis ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Hold rating on Kyverna Therapeutics, Inc. (KYTX – Research Report). The ...

IGM Biosciences has collaboration deal with Sanofi inked in 2022 and its stock has almost doubled in 2024 year to date. Read ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

The life sciences landscape has changed significantly in recent decades, and will continue to do so at pace.1 The rise of ...

The Neuromuscular Disease Center has a long history of providing excellent clinical care and research in myasthenia gravis. Myasthenia gravis is a chronic autoimmune disorder that causes muscle ...